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COriginal article 713Claims in advertisements for antihypertensive drugs in a
Dutch medical journal
Jacoba P. Grevinga, Petra Deniga, Dick de Zeeuwa and
Flora M. Haaijer-RuskampaBackground Advertising claims must not conflict with the
official summary of product characteristics. After a drug has
been approved, new clinical evidence may become
available.
Aims To determine how the pharmaceutical industry deals
with evolving clinical evidence in advertising claims for
antihypertensive drugs, and whether such pharmaceutical
promotion is up to standard.
Methods We examined all advertisements from the
Dutch Journal of Medicine published between 1996 and
2004. We judged whether claims were in agreement with the
information available from the summary of product
characteristics or evidence from cited clinical trials.
Subsequently, we reviewed whether these claims had been
assessed by the Code of Practice authority.
Results We identified 50 unique advertisements with, in
total, 492 appearances for 16 antihypertensive drugs.
Claims of blood pressure lowering and convenient use were
all judged to be sufficiently substantiated. For calcium-
channel blockers, insufficiently supported safety claims had
been made in three cases (41 appearances). Claims
suggesting effects on long-term outcomes started in 1999
for angiotensin II receptor blockers, and were made during
the whole period for several other antihypertensive drugs.
In 16 cases (135 appearances), such claims were not
supported by the available information. Some claims
were premature, others transferred results from a specificopyright © Lippincott Williams & Wilkins. Unauth
0263-6352  2007 Lippincott Williams & Wilkinspatient group to the general population of hypertensive
patients. Only two cases were reviewed by the Code
of Practice authority.
Conclusions Overall, 35% of the advertisements for
antihypertensive drugs contained suggestive claims not
supported by the offered evidence. The current system of
self-regulation cannot ensure that pharmaceutical
promotion is always accurate, balanced and evidence-
based. J Hypertens 25:713–722 Q 2007 Lippincott Williams
& Wilkins.
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Concerns about the quality of drug advertising have
existed for many years. Several studies have documented
inaccuracies and misleading claims in drug advertisements
[1–7]. Individual countries have dealt with this problem in
various ways. In Europe, the advertising of medicinal
products was harmonized by the Council Directive
1992/28/EEC. In The Netherlands, this Directive was
implemented in the form of the Medicinal Products
Advertising Decree in 1994. Governments in Europe,
Canada and Australia have ceded control of pharmaceu-
tical promotion to Code of Practice authorities. These
authorities have developed self-regulatory pharmaceutical
advertising codes of conduct to which pharmaceutical
companies are expected to adhere. According to these
regulations, all claims concerning drugs should be accu-
rate, up to date, truthful, correct, verifiable and may not be
misleading [8,9]. Advertising claims must not in any wayconflict with the officially approved summary of product
characteristics and must encourage rational drug use [8].
Before a new drug is allowed on the market, it is tested in
clinical trials to show its safety and efficacy, at least in
terms of intermediate outcomes. This information is
included in the summary of product characteristics,
and can be used in advertising claims. Once on the
market, new information may become available about
side effects and long-term outcomes. In addition, new
evidence on similar drugs belonging to the same drug
class can become available. It is not clear how the
pharmaceutical industry deals with this evolving clinical
evidence in their advertising claims. Up to now, studies
on pharmaceutical advertising only documented the
quality of claims in a particular year, and did not inves-
tigate how new research findings were presented in the
advertisements over time [3–7]. Better insights into thisorized reproduction of this article is prohibited.
C714 Journal of Hypertension 2007, Vol 25 No 3process can help us identify whether current self-
regulatory codes have been effective in ensuring that
pharmaceutical promotion is up to standard.
We investigated trends in advertising claims for antihy-
pertensive drugs in a Dutch medical journal over a 9-year
period, determining whether claims were substantiated
by scientific evidence in this period.
Methods
Data collection
We reviewed pharmaceutical advertisements appearing
between 1 January 1996 and 31 December 2004 in the
Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of
Medicine). This medical journal is published weekly and is
among the most widely circulated medical journals in
The Netherlands (circulation of 32 000 in 2004). Regard-
ing advertisements for antihypertensive drugs, we
recorded brand names and therapeutic class [diuretics,
beta-blockers, calcium channel blockers, angiotensin-
converting enzyme inhibitors (ACE inhibitors) and
angiotensin II receptor blockers (ARBs)] in the 466
retrieved issues. Advertisements for antihypertensives
which differed in text from other advertisements were
defined as unique advertisements.
Advertisement classification
We reviewed the information content of each unique
advertisement. We classified each promotional claim as
stating or suggesting:opyright © Lippincott Williams & Wilkins. Unautho




March, 1996 CCB co-medication to
pravastatin versus placebo
TREND [11] August, 1996 ACE versus placebo
STONE [12] Oct, 1996 CCB versus placebo
SYST-EUR [13] Sept, 1997 CCB versus placebo
BANFF [14] Jan, 2000 ACE versus ARB versus CCB
INSIGHT [15] July, 2000 CCB versus diuretic
QUO VADIS [16] March, 2001 ACE versus placebo
IDNT [17] Sept, 2001 ARB versus placebo; CCB
versus placebo; ARB versus
CCB
RENAAL [18] Sept, 2001 ARB versus placebo
IRMA-2 [19] Sept, 2001 ARB versus placebo
Val-HeFT [20] Dec, 2001 ARB versus placebo
LIFE [21] March, 2002 ARB versus BB
VALUE [22] June, 2004 ARB versus CCB
















B, beffects on intermediate outcomes (e.g. lowering
blood pressure)(2) effects on long-term outcomes (e.g. effects beyond
intermediate outcomes, including prevention or
reduction of cardiovascular and/or renal disease or
mortality, by using statements such as ‘effects on
end-organs’, ‘protection’ or ‘risk reduction’)(3) safety (e.g. excellent tolerability, placebo-like side-
effect profile)(4) convenience (e.g. low frequency of dosage, no drug
interactions)(5) costs (e.g. low price, cost-effective)
(6) new formulation
(7) indications other than hypertension.Next, we judged whether the claims were substantiated
by cited clinical trials (Table 1) [10–22] or information in
the officially approved summary of product character-
istics. In our assessments, we followed the standpoint of
the regulatory agencies, i.e. that positive effects on long-
term outcomes can not be derived from proven efficacy
on intermediate outcomes. All claims were evaluated
independently by three reviewers. Individual classifi-
cations were compared and, in case of discrepancy, the
advertisement was reviewed again and discussed until a
consensus was reached. Claims were categorized as:
supported by information in summary of product charac-
teristics (SPC) or a cited clinical trial that was designed to
assess this claim and published in a peer-reviewed journal
(þ); only supported by a cited trial that was either not yeted reproduction of this article is prohibited.
m 1996 to 2004
ajor findings
CBs may have a beneficial effect on the evolution of coronary
atherosclerosis in patients treated with lipid-lowering therapy.
However, the REGRESS trial was not designed to study the effect
of CCB administration, and no definite conclusions can be drawn
concerning the beneficial effect of adding a CCB to lipid-lowering
therapy
uinapril improves endothelial dysfunction in normotensive patients
ifedipine diminishes the number of strokes and cardiovascular events
in elderly hypertensives
itrendipine reduces the risk of stroke and various other cardiovascular
complications among elderly patients with isolated systolic hypertension
nly quinapril is associated with improvement in flow-mediated
vasodilatation in patients with coronary artery disease
ifedipine and co-amilozide were equally effective in preventing overall
cardiovascular or cerebrovascular complications
uinapril significantly reduced clinical ischaemic events within 1 year after
coronary artery bypass grafting
besartan is effective in protecting against the progression of nephropathy
due to type 2 diabetes, independent of the achieved reduction in blood
pressure
sartan confers significant renal benefits in patients with type 2 diabetes
and nephropathy, and it is generally well tolerated
besartan is renoprotective independently of its blood pressure-lowering
effect in patients with type 2 diabetes and microalbuminuria
alsartan significantly reduces mortality and morbidity in patients with heart
failure not treated with ACE inhibitors
sartan prevents more cardiovascular morbidity and death than atenolol for
similar reduction in blood pressure and is better tolerated
o difference in cardiac morbidity and mortality between valsartan and
amlodipine
ta-blocker; CCB, calcium channel blocker.
CClaims in advertisements for antihypertensive drugs Greving et al. 715published or not designed to assess this effect for this
drug in hypertensive patients (); or not supported by
information in the SPC or a reference to a clinical trial
(). The first category represents claims that are con-
sidered sufficiently supported.
Subsequently, we examined whether the Code of Prac-
tice authority in The Netherlands had reviewed any of
the advertising claims during the study period (CGR
Foundation; available at http://www.cgr.nl).
Analyses
To assess trends, we calculated the proportion of adver-
tisements for each antihypertensive drug class of all
advertisements for antihypertensive drugs per year. To
show the proportion of specific claims made for each drug
class, we calculated the number of appearances of each
type of claim divided by the total number of advertise-
ments made for that class.
Results
Trends in advertisements
We identified a total of 492 advertisements for antihy-
pertensive drugs during the period 1996–2004 in the
Dutch Journal of Medicine. Of these, 290 (59%) were
advertisements for ARBs, and 202 for calcium channel
blockers and/or ACE inhibitors. No advertisements for
ARBs were observed in 1996, but ARBs have been the
most frequently advertised antihypertensive drug class
since 1998 (Fig. 1). There were no advertisements for any
of the other antihypertensives after 2001.
Overall, 28 unique advertisements appeared for seven
ARBs, nine unique advertisements for ACE inhibitors or
combinations with ACE inhibitors, and 13 unique adver-
tisements for calcium channel blockers. There was a large
variety in patterns of advertising, both in quantity and















































Time trends in the proportion of the total number of advertisements for
antihypertensive drugs devoted to different classes of antihypertensive
drugs from 1996 to 2004. *, Angiotensin II receptor blockers; ,
angiotensin-converting enzyme inhibitors;~, calcium-channel blockers.and eprosartan were advertised continuously throughout
the study period, whereas advertisements for losartan,
valsartan and telmisartan only appeared for limited time
periods (Table 2).
Trends in claims
During the whole study period, claims were made regard-
ing efficacy in lowering blood pressure (Tables 2 and 3).
In total, 80% (233/290) of the advertisements for ARBs
included such a claim, and 52% (106/202) of the adver-
tisements for other antihypertensives. Claims suggesting
effects on long-term outcomes appeared in almost all
advertisements for the ACE inhibitors and one of the
calcium channel blockers. For ARBs, such claims started
in 1999, and were made in 29% (85/290) of the adver-
tisements. Approximately half (157/290) of the advertise-
ments for ARBs stated a claim of safety, but their
frequency decreased dramatically by 2000. No safety
claims were made for ACE inhibitors. Three of the
calcium channel blockers had an advertisement running
for less than 1 year in which safety claims appeared.
Convenience in use was used in a minority of the adver-
tisements, and costs were mentioned in only one. One of
the calcium-channel blockers was only advertised for the
indication angina pectoris.
Assessment of claims
Many claims were brief and non-specific. Claims regard-
ing efficacy in lowering blood pressure and convenient
use were all judged to be sufficiently substantiated by the
available information in the summary of product charac-
teristics. Regarding safety of ARBs, only vague claims
were made like ‘excellent tolerability’ or ‘placebo-like
side effect profile’ which were substantiated with the
information in the summary of product characteristics.
No specific claims were made, for instance, referring to
the low incidence of side effects such as cough and
angioedema or high persistence rates on ARBs. Safety
claims for calcium channel blockers were more specific,
including ‘less chance of headache, flush and oedema’ for
lercanidipine, and ‘modest incidence of typical side
effects as oedema, headache, flushing, and constipation’
for mibefradil. There were no references to peer-
reviewed publications to substantiate these claims. Only
references were provided to reports in supplements of
journals. For barnidipine a more general claim of ‘favour-
able side effect profile’ was made. In the summary of
product characteristics of barnidipine, side effects such as
headache, flushing and oedema were all classified as
‘occurring frequently (>1%, <10%) but they may dimin-
ish after 2–4 weeks’. Overall, advertisements claiming
positive side-effect profiles for calcium-channel blockers
appeared 41 times, constituting 31% of all advertisements
for these drugs.
The claims that were classified as stating or suggesting
effects beyond intermediate outcomes are presented inorized reproduction of this article is prohibited.
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Losartan 1995–1996 – – – – – – – – –
(March 1995) 1997 10 Hyzaar X X
1998–2000 – – – – – – – – –
2001 12 Cozaar X X X X
2001–2002 13 Cozaar X
2002 4 Cozaar X X X
2003–2004 – – – – – – – – –
Valsartan 1996–2001 – – – – – – – – –
(Nov. 1996) 2002 2 (Co-)Diovan X X
2003 – – – – – – – – –
2004 6 (Co-)Diovan X X X
2004 1 (Co-)Diovan X X
2004 5 Diovan X X X
2004 2 Co-Diovan X X X
Irbesartan 1997–1998 18 Aprovel X X
(Aug. 1997) 1998–1999 23 Aprovel X X
1999–2000 23 (Co-)Aprovel X X
2000–2001 17 (Co-)Aprovel X
2002 3 Aprovel X
2002–2003 8 Aprovel X
2004 4 (Co-)Aprovel X X
Candesartan 1997 – – – – – – – – –
(Oct. 1997) 1998 18 Atacand X X
1998–2000 32 Atacand X X
2000–2001 12 Atacand X
2000–2001 11 Atacand (Plus) X X
2002–2004 – – – – – – – – –
Eprosartan 1998–1999 – – – – – – – – –
(Jan. 1998) 2000–2002 18 Teveten
2002–2003 6 Teveten X
2004 6 Teveten X X X
Telmisartan 1999–2000 17 Micardis X X X X
(Dec. 1998) 2001–2002 – – – – – – – – –
2003 8 Micardis (Plus) X X X
2004 – – – – – – – – –
Olmesartan 2003 – – – – – – – – –
(May 2003) 2004 1 Olmetec X
2004 5 Olmetec X X
2004 5 Olmetec X X
Totalc 290 233 (80) 85 (29) 157 (54) 56 (19) 6 (2) 36 (12) 0 (0)
a In brackets is the date of regulatory approval in The Netherlands. b Number of times an advertisement with the same information content for the same trade name appeared.
c Total number of advertisements for angiotensin II receptor blockers; proportion of advertisements with a certain type of claim in brackets.Tables 4 and 5. For ARBs, these included four unique
advertisements (appearing 28 times in total) that were
considered to be sufficiently substantiated by the avail-
able evidence (Table 4). For example, ‘25% more risk
reduction for stroke’ (losartan), ‘renal protection and
prevention in hypertensive patients with type 2 diabetes’
(irbesartan) were substantiated by the cited trials. In
eight cases, claims were not considered to be sufficiently
substantiated by cited clinical trials or information in the
summary of product characteristics. Advertisements with
these claims appeared 57 times, which constituted 20% of
all advertisements for ARBs. The claim ‘23% reduction of
new-onset diabetes’ (valsartan) was supported by the
VALUE trial, but this was not a primary endpoint of this
trial. For losartan, the first of a series of three uniqueopyright © Lippincott Williams & Wilkins. Unauthoadvertisements with claims regarding effects on end-
organs was considered premature. At that time, results
from clinical trials showing long-term benefits were not
yet published and the cited studies only showed effects
on intermediate outcomes. In the first advertisement for
valsartan, results on hard endpoints in heart failure
patients were used in claims for an agent registered only
for hypertension. In three subsequent advertisements,
the claims ‘valsartan protects’ and ‘a few millimetres
reduction in blood pressure decrease gives kilometres
cardiovascular protection’ were made, which suggest
beneficial effects on morbidity or mortality in hyperten-
sive patients for which no evidence was provided. For
irbesartan, the claim of long-term benefits was expanded
to hypertensive patients in general in the last of a series ofrized reproduction of this article is prohibited.
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Lisinopril 1996–1999 – – – – – – – – –
(October 1988) 2000 4 Zestril X X
2001–2004 – – – – – – – – –
Quinapril 1996 11 Acupril X
(August 1990) 1996–1997 8 Acuzide X X
1997 12 Acupril X X
1997–1998 17 Acupril X X X
1998–1999 17 Acupril X X X
2000–2004 – – – – – – – – –
Verapamil 1996 – – – – – – – – –
(November 1988) 1997 5 Isoptin SR
1998–2004 – – – – – – – – –
Nifedipine 1996 7 Adalat X
(October 1991) 1996–1998 10 Adalat X
1998 3 Adalat X
1999–2000 10 Adalat X X
2000–2001 5 Adalat X
2002–2004 – – – – – – – – –
Diltiazem 1996 8 Tildiem XR X
(October 1994) 1997–1998 – – – – – – – – –
1999 1 Tildiem XR X
2000 2 Tildiem XR X
2001–2004 – – – – – – – – –
Lercanidipine 1996 – – – – – – – – –
(April 1997) 1997–1998 24 Lerdip X X
1999–2004 – – – – – – – – –
Mibefradil 1996 – – – – – – – – –
(August 1997)c 1997 12 Posicor X X X X
1997–1998 13 Posicor X X
Barnidipine 1996–1999 – – – – – – – – –
(June 1999) 2000 5 Cyress X X X
2001–2004 – – – – – – – – –
Trandopril/verapamil 1996 1 Tarka
(March 1995) 1996–1998 16 Tarka X
1998 11 Tarka X
1999–2004 – – – – – – – – –
Totald 202 106 (52) 131 (65) 41 (20) 34 (17) 0 (0) 0 (0) 69 (34)
a In brackets is the date of regulatory approval in The Netherlands. b Number of times an advertisement with the same information content for the same trade name appeared.
c Withdrawn from the market in June 1998. d Total number of advertisements for antihypertensive drugs other than angiotensin II receptor blockers; proportion of
advertisements with a certain type of claim in brackets.three unique advertisements. Finally, for telmisartan two
advertisements appeared over 3 years, in which the words
‘protection in early morning hours’ were used, partly in
combination with a remark that this correlates with early
morning cardiovascular events.
For the other four antihypertensive drugs with claims
suggesting or stating effects on long-term outcomes
(Table 5), one was substantiated by the summary of
product characteristics (lisinopril), and another by a num-
ber of cited trials (nifedipine). However, in the first seven
advertisements this claim was based on ‘upcoming
results’ which had not yet been published in a peer-
reviewed journal. For quinapril, at first no trials wereopyright © Lippincott Williams & Wilkins. Unauthcited to substantiate the claim of ‘extra protection against
end-organ damage’ but later the TREND study was cited
as evidence for improving endothelial function, and
finally a preliminary report related to the QUO-VADIS
study was cited to support the claim of reducing the risk
for ischaemic events. This study, however, was con-
ducted in patients after coronary artery bypass grafting.
For the combination product of an ACE inhibitor with a
calcium channel blocker, first a vague claim of ‘protection
in hypertensives’ was made, which was followed by an
advertisement claiming ‘extra protection now... for later’.
These claims were not substantiated by cited clinical
trials or information in the summary of product charac-
teristics. In total, there were 78 advertisements fororized reproduction of this article is prohibited.
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Table 4 Claims for angiotensin II receptor blockers suggesting or stating effects on long-term outcomes
Product Claim (literal translation) Period No. of ad. appearancesa Support for this claimb




12 (1)  Cited clinical trials only showed effect on intermediate outcomes
‘proven renal protection
in hypertensive patients




13 (1) þ Cited RENAAL trial showed renoprotective effect of
losartan in hypertensive patients with type 2 diabetes




4 (1) þ Cited LIFE trial showed that losartan prevents more morbidity
and death than atenolol in hypertensive patients
Valsartan ‘significant reduction in
mortality and morbidity,
as proven in Val-HeFT’
June 2002 2 (1)  Study population of the cited Val-HeFT trial consisted of heart
failure patients, while heart failure was not an approved
indication for valsartan
‘valsartan protects’ January 2004 to
April 2004
6 (1)  No cited trial or information in SPC showing beneficial effects of
valsartan on mortality or morbidity in hypertensive patients
‘23% reduction of new-onset
diabetes’
July 2004 1 (1)  In the cited VALUE trial new-onset diabetes arose in fewer patients
on valsartan than on amlodipine but this was not a primary
endpoint of the trial
‘a few millimetres reduction





7 (2)  No cited trial or information in SPC showing beneficial effects of
valsartan on mortality or morbidity in hypertensive patients
Irbesartan ‘renal protection and
prevention in hypertensive




3 (1) þ Both the cited IDNT trial and IRMA-2 trial showed renoprotective
effect of irbesartan in hypertensive patients with type 2 diabetes
‘first ARB with an additional
indication: treatment of
nephropathy in hypertensive
patients with type 2 diabetes’
September 2002 to
November 2003
8 (1) þ Based on results of the IDNT trial and IRMA-2 trial, irbesartan
received the approval for this additional indication in SPC





4 (1)  No cited trial or information in SPC showing risk reduction of
irbesartan in hypertensive patients in general




17 (1)  The cited study assessed the antihypertensive effect and duration
of action of telmisartan but not any protective effects. SPC states
that beneficial effects of telmisartan on mortality and
cardiovascular morbidity are currently unknown
‘. . . offers protection against
early morning peaks in blood
pressure, which fall together




8 (1)  The studies cited assessed the antihypertensive effect and
duration of action of telmisartan, and did not show beneficial
effects of telmisartan on cardiovascular events
SPC, summary of product characteristics. a Number of times this advertisement with this claim appeared; number of unique advertisements in brackets. b Supported by
information in SPC or a cited clinical trial that was designed to assess this effect (þ), only supported by a cited trial that was either not yet published or not designed to
assess this effect for this drug in hypertensive patients () or not supported by information in the SPC or a reference to a clinical trial ().antihypertensive drugs other than ARBs with claims
for effects that were considered not sufficiently sup-
ported, which constituted 39% of all advertisements for
these drugs.
Complaints about promotional material
During the study period, the Code of Practice authority
received complaints regarding two of the claims that we
considered as being problematic. One of the complaints
focused on the claim ‘significant reduction in mortality
and morbidity, as proven in Val-HeFT’ and another
complaint was made for the claim ‘valsartan protects’.
The complainant alleged that claims using results from
the Val-HeFT trial, which consisted of heart failure
patients, suggested that heart failure was an approved
indication for valsartan. The authority, however, did not
rule on this complaint. Regarding the claim ‘valsartan
protects’, the authority took the view that this was not in
breach of the code since it was generally known that
lowering blood pressure reduces the risk of end-organopyright © Lippincott Williams & Wilkins. Unauthodamage. After this ruling in 2001, the complainant also
felt free to make general claims of risk reduction for an
ARB without further supporting evidence.
Discussion
To our knowledge, this is the first study to assess the
effects of evolving clinical evidence on pharmaceutical
marketing claims in journal advertisements. We found
that ARBs have been the most frequently advertised
antihypertensive drug class in The Netherlands since
1998. While awaiting the results of large clinical trials,
ARBs were mostly promoted using claims of their efficacy
in lowering blood pressure and their excellent safety
profile. These claims were all substantiated by infor-
mation available at the time of regulatory approval.
Starting in 1999, claims suggesting efficacy beyond blood
pressure lowering were observed for ARBs, several of
which were not supported by clinical trials or information
in the summary of product characteristics. Similar claims
were made in advertisements for ACE inhibitors and onerized reproduction of this article is prohibited.
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Table 5 Claims for antihypertensive drugs other than angiotensin 2 antagonists suggesting or stating effects on long-term outcomes
Product Claim (literal translation) Period No. of ad. appearancesa Support for this claimb




4 (1) þ Lisinopril received approval for this
additional indication in SPC




19 (2)  No cited trial or information in SPC
showing beneficial effects on
end-organs
‘. . . protects/restores the
endothelial function. . . thus
provides an early intervention




29 (2) þ The cited TREND study demonstrated
improvements in endothelial function.
The SPC states that endothelial
dysfunction is considered to be
important in the process underlying
coronary heart disease




17 (1)  The results of the cited QUO VADIS
trial were not yet published. Moreover,
this trial was designed to explore
whether quinapril would decrease
ischaemia in patients who underwent
coronary artery bypass grafting
‘. . . only antihypertensive drug
that significantly improves the
endothelial function’
 The results of the cited BANFF study
that was designed to demonstrate
effects on flow-mediated vasodilation
were not yet published






A significant reduction in relative
risk was observed for strokes in
the cited STONE study but the
first seven advertisements appeared
when the results were not yet
published in a peer-reviewed
journal
‘. . . delays the process of
atherosclerosis’; ‘50% fewer
patients with new lesions’
August 1998 to
December 1998
3 (1)  In the cited REGRESS trial beneficial
effects of CCBs on the evolution of
coronary atherosclerosis in patients
treated with lipid-lowering therapy
were observed but this trial was not
designed to study the effect of CCBs
‘the certainty of 24 hours protection.
Protection now and in the future’;




10 (1) þ The cited STONE and Syst-EUR trials
showed that nifedipine and nitrendipine
reduced the risk of stroke and other
cardiovascular events in the elderly
‘. . . reduces the risk to develop
cardiovascular events with 50%’
September 2000 to
March 2001
5 (1)  The cited INSIGHT trial showed that
nifedipine and co-amilozide were
equally effective in preventing
cardiovascular and cerebrovascular
complications but does not support
the claim of 50% risk reduction
Trandopril/verapamil ‘protection in hypertensive patients’ January 1996 to
January 1998
16 (1)  No cited trial or information in SPC
showing beneficial effects of
trandopril/verapamil on mortality
or morbidity in hypertensive patients
‘extra protection now. . . for later’ February 1998 to
December 1998
11 (1)  No cited trial or information in SPC
showing beneficial effects of
trandopril/verapamil on mortality or
morbidity in hypertensive patients
SPC, summary of product characteristics; CCBs, calcium-channel blockers. a Number of times this advertisement with this claim appeared; number of unique
advertisements in brackets. b Supported by information in SPC or a cited clinical trial that was designed to assess this effect (þ), only supported by a cited trial that
was either not yet published or not designed to assess this effect for this drug in hypertensive patients () or not supported by information in the SPC or a reference to a
clinical trial ().of the calcium channel blockers. Again, several were not
substantiated by the cited evidence or information in the
summary of product characteristics. In addition, specific
claims were made regarding favourable side effect pro-
files of some of the calcium channel blockers that were
not sufficiently supported. In total, 35% of the advertise-
ments for antihypertensive drugs contained suggestive
claims not supported by the offered evidence.opyright © Lippincott Williams & Wilkins. UnauthIt is well known that the pharmaceutical industry spends
large amounts of money on promoting its products. This
is particularly the case in a field in which several drugs
compete for the same patient population, and pharma-
ceutical companies need to develop campaigns to dis-
tinguish between almost identical products. Under these
circumstances, clinical research on long-term outcomes
becomes part of a race to obtain results to strengthen theorized reproduction of this article is prohibited.
C720 Journal of Hypertension 2007, Vol 25 No 3market position of a drug. Previous studies showed that
the number of references to clinical trials in drug adver-
tisements has increased in recent years, but many claims
were still not adequately substantiated by these refer-
ences [5–7]. These findings are troublesome, since
research shows that drug advertising serves as an import-
ant source of information for physicians [23,24]. Although
many physicians perceive themselves as paying little
attention to drug advertisements, advertising has been
shown to influence physicians’ beliefs about the effec-
tiveness of drugs [23].
In our study we also observed advertisements with
imprecise interpretation of scientific evidence. Some-
times claims were premature, as in the examples of both
nifedipine and losartan, where claims on hard endpoints
were made before the first supporting trial results became
available. Although with hindsight one could argue that
these claims were correct, at that time they were not
sufficiently substantiated. It has been shown that claims
based on results that have not yet been scrutinized and
published in a peer-reviewed journal, can be overly
optimistic [25]. In other cases, scientific evidence was
provided on a restricted claim but presented in a broader
context. Examples are advertisements for valsartan and
quinapril as being antihypertensive drugs, for which risk
reduction claims were made using trials evaluating
effects in heart failure patients or patients after coronary
artery bypass grafting. Another example is the advertising
for irbesartan that, after a period of using specific claims
clearly substantiated by clinical trials, included a more
general claim that was not based on such evidence.
Finally, claims were sometimes made without any cited
evidence. In some cases, these were general claims of
‘protection’ but the example of quinapril shows that even
specific claims on hard endpoints have been made with-
out providing any supporting evidence. We defined gen-
eral claims of ‘protection’ or ‘risk reduction’ as claims
suggesting beneficial effects on long-term outcomes.
This position was also taken by the Code of Practice
authority when they reviewed one of these claims, but
they did not object to using such a claim for a drug that
had only been proven to lower blood pressure. This
differs from the standpoint of the regulatory agencies
that we used in our assessments, namely that positive
effects on long-term outcomes can not be derived from
proven efficacy on intermediate outcomes. After this
ruling of the Code of Practice authority, another manu-
facturer also felt free to make general claims of risk
reduction without further supporting evidence.
For some calcium channel blockers claims were made
regarding ‘less side effects’ or ‘favourable side effect
profiles’. This suggests that these drugs have fewer side
effects than other calcium-channel blockers (or even
other antihypertensives). In some cases, references to
journal supplements were given, which we did not con-opyright © Lippincott Williams & Wilkins. Unauthosider as offering sufficient evidence because they often
lack the scrutiny of a peer-reviewed publication. When
the summary of product characteristics reported that side
effects occur frequently (between 1 and 10%), we con-
sidered the claim as not being substantiated since this is
not favourable compared to other antihypertensives. We
assessed claims of ‘placebo-like side effect profile’ as
sufficiently substantiated when the summary of product
characteristics mentioned that the incidence pattern of
side effects was comparable to that of a placebo. In the
UK, however, complaints about claims of ‘placebo-
like tolerability’ for both valsartan and irbesartan were
reviewed in 2003 and 2004 by the Medicines and Health-
care products Regulatory Agency (MHRA; the cases are
in the section advertising complaints published on 2 April
2004 and 5 May 2004, available at http://www.mhra.
gov.uk). This governmental agency, which is comple-
mentary to the self-regulation by the pharmaceutical
industry, considered this claim to be misleading as it
implied that there were no drug-associated side effects
and suggested that the product was ‘safer’ than alterna-
tive medicines. In this respect the MHRA appears to take
a different position than the self-regulatory Prescription
Medicines Code of Practice Authority in the UK, which
accepted that ‘placebo-like tolerability’ was a character-
istic that could be attributed to various agents in the class
of ARBs (the case is in the Code of Practice Review,
number 30, November 2000, available at http://www.
abpi.org.uk/links/assoc/pmcpa.asp).
Regulations and self-regulatory systems are probably
effective in preventing some drug promotion abuses by
providing the opportunity to submit complaints and by
ruling against code violations [6]. Clear violations of
specific requirements, such as referring to a clinical trial
before it is published, were judged as breaching the Code
of Practice. Rules on vague or suggestive claims are more
difficult to make. Only two of the claims we considered as
being problematic were reviewed by the Code of Practice
authority. We do not know how many complaints were
settled out of court.
These findings show the potential weaknesses of the
current system in our country. It has been suggested that
there should be an active monitoring system for recog-
nizing violations, independent monitoring committees,
and effective sanctions for code violations [3,7,26,27].
The British example clearly shows that a governmental
committee may be more critical in judging whether a
claim might mislead the prescribers than a self-regulatory
authority. Apart from stricter control of the regulations, it
has also been recommended that the regulations be
tightened up [28]. Some specific requirements could
be formulated to counter the problems observed here.
One could think of rules for mentioning the approved
indication, as well as the studied patient population on
which claims are based, clearly in the advertisementrized reproduction of this article is prohibited.
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required in advertisements for drugs that do not yet have
proven efficacy on relevant long-term outcomes. This
would be on a par with the European Medicines Agency
guidelines of 1997, which state that the summary of
product characteristics should mention explicitly when
beneficial effects on mortality and cardiovascular mor-
bidity are unknown, until the results from adequate trials
supporting this effect are available [29].
A strength of this study is that we collected data over a
long time period, enabling us to assess the effects of
evolving clinical evidence on marketing claims. During
the study period, new evidence regarding efficacy and
safety became available for the drugs studied. There are
some limitations. First, although we investigated all
journal advertisements in the most widely circulated
national medical journal, this may not reflect the fre-
quency or types of claims in other medical journals, nor in
other types of promotion. Second, we assessed the textual
content of the advertisements, whereas drugs are pro-
moted through text as well as colourful, attention-
grabbing images that can also inform and mislead the
reader [1]. Finally, our study was confined to The
Netherlands. Although the evidence used to support
advertising claims is universal, and there is a council
directive to harmonize drug advertising in the European
Union, systems of regulations may vary between
countries. Our study therefore gives one example of
how this directive is implemented in practice.
In conclusion, this study showed that just over a quarter
of the evaluated advertisements for antihypertensive
drugs contained claims suggesting benefits beyond blood
pressure control that were not sufficiently supported by
the cited scientific evidence or the summary of product
characteristics. Most of these claims were not reviewed
by the self-regulatory authority. At this moment, phys-
icians cannot fully rely on this system of self-regulatory
codes for pharmaceutical promotion. Before drawing
conclusions from advertising claims, they need to inves-
tigate the supporting information themselves. An
additional monitoring agency and tightened rules might
help to ensure that pharmaceutical promotion is accurate,
balanced and evidence-based.
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